Health

Octapharma USA announces FDA approval of cutaquig 16





Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has approved cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig® for adults with PI.

“The FDA approval provides physicians and families with more treatment options for patients with primary immune disorders, which weaken the immune system and can allow infections and other health issues to occur more easily,” said Roger H. Kobayashi, M.D., Clinical Professor UCLA School of Medicine and National Consultant, Immune Deficiency Foundation. “The FDA approval also provides more flexible options by permitting more frequent or less frequent infusions, which can be advantageous based on a patient’s pharmacokinetic and clinical response.”

Patients and providers have the flexibility to administer cutaquig® at a lower dose more frequently or at a larger dose less frequently if desired. Patients who prefer less frequent injections may have the option of receiving therapy every other week. At the same time, physicians can prescribe daily dosing if patients respond better to more frequent therapy.

Cutaquig® provides enhanced convenience for a wider group of patients who want to customize therapy with their prescriber to best match patient lifestyle needs,” said Octapharma USA President Flemming Nielsen. “Octapharma is committed to providing people with immune disorders the life-saving therapies they need. Both the addition of the pediatric indication and the flexible dosing illustrate our commitment to ensure patients have access to lifesaving products that offer a variety of choices for therapy delivery.”

Flemming Nielsen, President, Octapharma USA

The FDA approval of cutaquig® is based on the results of two clinical trials, which observed 75 PI patients, 37 adults and 38 pediatric patients between ages 2 and 17. The patients received weekly infusions with cutaquig® during a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main objective of the research was to assess the efficacy of cutaquig® in preventing serious bacterial infections, defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess. No serious bacterial infections were reported.

Read The Full Article Here

My Life As A Mother With A High Potential Child
The Secret Advice No Therapist Will Ever Give You About Grieving a Loved One
Teach Your Teenagers How To Manage Jealous People
5 Principles To Talk About God And Abundance To Your Kids
Prince Harry Opens Up About When He Knew Meghan Markle
Rich Pregnant vs Broke Pregnant
How To Watch The Perseid Meteor Shower With Your Family
10 Tips For PREGNANT Women
Baby Care Tips
How to Care a newborn kitten
Main Tota Hare Rang Ka
Drug Free Kids
My Child Is Afraid of Vomiting And This Creates A Lot Of Discomfort In Our lives!
My Life As A Mother With A High Potential Child
5 Principles To Talk About God And Abundance To Your Kids
AWESOME TOY CARS MODARRI Building CUSTOM CAR! Kids Review!
My Child Is Afraid of Vomiting And This Creates A Lot Of Discomfort In Our lives!
My Life As A Mother With A High Potential Child
The Secret Advice No Therapist Will Ever Give You About Grieving a Loved One
Teach Your Teenagers How To Manage Jealous People
Child Development: Are You Anxious About Autistic Risks?
Autism: Tools To Adapt Yourself To Your Child’s Emotions And Unexpressed Requests
The Psychological Contents of Halloween
Quality Moments: Learn Navajo with your child!
DAYCARE SCHEDULE
Make a Colorful Flying Snake Out of a Paper Plate